Leila Mandlsohn is Director, Drug Reviews & Pharmaceutical Partnerships at Sun Life, where she leads the organization’s drug review strategy and advances innovative approaches to pharmaceutical partnerships within Group Benefits.
In her role, Leila focuses on how private payers can enable sustainable access to medications and preventative services – working at the intersection of clinical evidence, plan design, and member experience. She is particularly engaged in advancing solutions that embed prevention, including vaccines, as a more consistent and accessible component of employer-sponsored health benefits.
Leila brings deep expertise across both Canadian and U.S. healthcare systems, with experience spanning frontline pharmacy practice, hospital care, and pharmaceutical benefit management. This perspective allows her to translate complex therapeutic and policy landscapes into practical strategies that improve access, reduce administrative burden, and support better health outcomes for Canadians.
She is passionate about strengthening collaboration across insurers, advisors, pharmacists, and industry stakeholders to improve the patient journey – particularly at the pharmacy counter, where access, coverage, and care delivery come together.